Tissue Regenix Group plc (LON:TRX – Get Free Report) reached a new 52-week low during trading on Thursday . The stock traded as low as GBX 43 ($0.56) and last traded at GBX 44.05 ($0.57), with a volume of 59470 shares changing hands. The stock had previously closed at GBX 45 ($0.58).
Tissue Regenix Group Stock Performance
The stock has a market cap of £38.54 million, a P/E ratio of -44.13 and a beta of 1.61. The company has a fifty day moving average price of GBX 54.61 and a 200 day moving average price of GBX 57.09. The company has a debt-to-equity ratio of 31.16, a current ratio of 4.03 and a quick ratio of 2.36.
Tissue Regenix Group Company Profile
Tissue Regenix is a leading medical device company in regenerative medicine. The Company’s patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient’s body that can be used to repair diseased or damaged body structures.
Featured Articles
- Five stocks we like better than Tissue Regenix Group
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
- How to Invest in Small Cap Stocks
- 3 Stocks to Buy While Others Stay on the Sidelines
- Learn Technical Analysis Skills to Master the Stock Market
- MarketBeat Week in Review – 03/03 – 03/07
Receive News & Ratings for Tissue Regenix Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tissue Regenix Group and related companies with MarketBeat.com's FREE daily email newsletter.
